Search

To systematically evaluate the clinical efficacy and safety of Lianhua Qingwen in the treatment of adult pneumonia. The randomized controlled trial of Lianhua Qingwen combined with conventional Western medicine in the treatment of pneumonia were retrieved from PubMed, EMbase, Wanfang database, VIP database, and CNKI from the establishment of database to March 2020. Two researchers independently conducted literature screening and data extraction, and the third researcher was in charge of arbitration in case of any disagreement. Outcome indicators included total clinical effective rate, symptom improvement time, and incidence of adverse events. R 3.6.1 was used for Meta-analysis, and RevMan 5.3 was used for quality evaluation. Twenty-two studies were included, with a total of 2 007 patients, including 1 017 patients in the experimental group and 990 patients in the control group. The results showed that the total clinical effective rate of the experimental group was higher than that of the control group(RR=1.11, 95%CI[1.08, 1.15], Plt;0.001), and the antifebrile time(MD=-1.81, 95%CI[-2.42,-1.21], Plt;0.001), cough duration(MD=-2.32, 95%CI[-2.89,-1.76], Plt;0.001), rale duration(MD=-2.19, 95%CI[-2.74,-1.63], Plt;0.001), imaging recovery time(MD=-2.17, 95%CI[-2.76,-1.58], Plt;0.001) and post-treatment CRP(MD=-4.07, 95%CI[-6.39,-1.75], Plt;0.001] were all significantly lower than those of the control group. However, it did not proved that the experimental group was safer than the control group(RR=0.84, 95%CI[0.57, 1.24], P=0.382). The results confirmed that Lianhua Qingwen combined with conventional Western medicine in the treatment of pneumonia could improve the clinical treatment efficiency, shorten the time of fever, cough, rale disappearance and imaging recovery, improve CRP index and accelerate the recovery of pneumonia patients. However, the literatures included in this study had a low quality, and the conclusions still need to be further confirmed by more high-quality, multi-center, rigorously designed randomized controlled trial.

Immobilizer and remote keyless entry (RKE) systems are widely used in the auto industry to improve the security and comfort. However, most of them have vulnerabilities which allow to recover the cryptographic key. In this paper, we present attacks to break the Hitag2-based immobilizer and RKE systems. These attacks require only several minutes of computation on a laptop after obtaining four to eight valid authentication traces, i.e., authentication messages between the immobilizer and the electronic key or rolling codes of the key. The attack on the immobilizer system can fully recover the cryptographic key which allows an adversary to authenticate to the vehicle and start the engine. The attack on the RKE system can determine the state of the last rolling code and predict the next rolling code. This allows an adversary to open the door quickly without leaving any physical traces. A combination of these two attacks provides the ability to open the door and start the engine of a Hitag2-based vehicle in minutes at a very low cost.

The clinical features and etiology of Budd-Chiari syndrome (BCS) vary from region to region, and there is lack of large sample studies about BCS in China. The aim of the present study was to study the clinical features and etiology of patients with incident BCS in China prospectively.A consecutive case series of patients with incident BCS who were diagnosed in the Affiliated Hospital of Xuzhou Medical College (Jiangsu, China) were enrolled from September 2010 to December 2011. All of the patients had continuous follow-ups to record the symptoms, body features, laboratory and radiology findings, and treatment methods through May 2012.A total of 145 incident cases of BCS were identified. BCS was caused by hepatic venous obstruction in 31% of the patients, inferior vena cava obstruction in 6% of the patients, and 63% suffered from a combination of the two conditions. At least one etiological factor was present in 82% of the patients, with the most common being membranous obstruction (61%). Only 5% of the patients had myeloproliferative neoplasms with a JAK2 V617F mutation, and none of the patients had a factor V Leiden mutation. Eighteen months after a percutaneous transluminal angioplasty was performed, the survival rate and the asymptomatic survival rate were 99% (95% confidence interval, 95-100%) and 93% (95% confidence interval, 89-98%), respectively.The most prevalent etiological factor for BCS in China is membranous obstruction. Moreover, most Chinese patients with chronic BCS are treated with percutaneous transluminal angioplasty and have an excellent clinical outcome.